Allergy Therapeutics PLC Grant of Options under Long Term Incentive Plan (9019R)
March 11 2016 - 11:36AM
UK Regulatory
TIDMAGY
RNS Number : 9019R
Allergy Therapeutics PLC
11 March 2016
11 March 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
confirms that certain performance conditions attaching to
provisional awards ("Awards") made pursuant to the Company's Long
Term Incentive Plan ("LTIP") for the three years ended 8 March
2015, details of which were announced on 15 May 2013, have been
met. Consequently, Allergy Therapeutics has today granted certain
of its directors low cost options ("Options") over the Company's
ordinary shares of 0.1 pence each ("Ordinary Shares") in
replacement for the Awards made under the LTIP as follows:
Director Number of Total number Total remaining
Ordinary of Ordinary number of
Shares over Shares over Ordinary
which Options which Options Shares provisionally
granted granted awarded under
LTIPs
Manuel Llobet,
Chief Executive
Officer 905,000 1,529,024 1,690,000
Ian Postlethwaite,
Finance Director 452,500 928,012 845,000
The Options have been granted in accordance with the LTIP rules
and can be exercisable between 11 March 2016 and 11 March 2026 at
an exercise price of 0.1p per Ordinary Share.
For further information please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSFMGMFVMDGVZM
(END) Dow Jones Newswires
March 11, 2016 11:36 ET (16:36 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024